LYSOSOMAL THERAPEUTICS
Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.
LYSOSOMAL THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.lysosomaltx.com
Total Employee:
1+
Status:
Active
Contact:
617-913-0166
Total Funding:
24.8 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Organization Schema Office 365 Mail GoDaddy DNS
Similar Organizations
AdiCyte
AdiCyte offers cryopreservation of adipose tissue and stem cells for patients in cosmetics, regenerative medicine and tissue engineering.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Alessa Therapeutics
Alessa Therapeutics develops localized treatments for solid organ disease.
AFX Medical
AFX Medical offers precision medicine for brain diseases.
Avrion Therapeutics
Avrion Therapeutics is a precision Gene Therapies for Neurodegenerative Diseases.
BEAT BioTherapeutics
BEAT BioTherapeutics develops novel therapies for heart diseases.
Betr Health
Betr Health delivers digital therapeutics solutions for weight management, hypertension, diabetes, hyperlipidemia, and digestive problems.
Biointaxis
Spinout from the Igtp for neurodegenerative rare diseases.
Brainreader
Brainreader develops software which detects neurodegenerative diseases.
Cadent Therapeutics
Cadent Therapeutics develops novel medicines that tune and modulate brain rhythms for patients with serious neurological disease.
Cajal Neuroscience
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Carbylan Therapeutics
Carbylan Therapeutics was founded in 2004
Celestial Therapeutics
Celestial Therapeutics specializes in the fields of biotechnology, therapeutics, and life science.
Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Convalesce
Stem Cell Based Therapy for Neurodegenerative diseases
ConverGene
ConverGene is a small molecule discovery company leveraging rational drug design.
Decedario
Decedario is a therapeutic board game for cognitive stimulation.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Empyrean Therapeutics
Empyrean Therapeutics develops next generation cell therapies to enable global and affordable cures for diseases.
Geometer
Geometer is entirely focused on helping with the current Covid-19 crisis.
GLyPharma Therapeutic
GLyPharma Therapeutic Inc. develops oncology drugs.
HbO2 Therapeutics
HbO2 Therapeutics develops and manufactures oxygen carrying solutions.
Iaso Therapeutics
Iaso Therapeutics develops vaccines to improve human health and cure diseases.
Immunity Pharma
Immunity Pharma specializes in developing therapies for neurodegenerative diseases.
Inflammasome Therapeutics
Inflammasome Therapeutics Inc found to develop therapies for prevalent, degenerative diseases.
INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE
ISCRM is working to transform therapies for heart failure, neurodegenerative diseases.
Kaya Ventures
Kaya Ventures provides building a healthier, happier, and more empowered future.
Level
Level is a mental healthcare solution delivered to employees anywhere via the Level app.
Intrinsic Medicine
New Medicines for Underserved Gut-Brain-Axis Disorders
MitoChem Therapeutics
MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction in neurodegenerative, aging, and disease.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Neuradom
Neuradom specializing in the home support of people with neurodegenerative diseases.
NeuroInitiative
Neuroinitiative is dedicated to the advancement of research and understanding two neurodegenerative disorders, Alzheimer’s & Parkinson’s
Neuromagen Pharma
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.
Novel Therapeutic Technologies
Novel Therapeutic Technology develops practical drug delivery systems.
Padlock Therapeutics
Padlock is developing medicines targeting PADs, immune complexes in autoimmune diseases, and more.
Peptineo
Peptineo provides Nano-based therapeutics for existing and emerging diseases.
Promakhos Therapeutics
Promakhos Therapeutics provides a therapeutics platform for curing inflammatory disorders.
ProNeurotech
ProNeurotech is a developer of neuroprotective drugs that prevent axon loss after acute injury or chronic degenerative disease.
Rarebase
Biomedical R&D for Rare Disease
REMD Biotherapeutics
REMD Biotherapeutics provides medications for chronic illnesses such as metabolic diseases.
Rodin Therapeutics
Rodin Therapeutics develops novel therapeutics for neurological disorders by applying insights of epigenetics.
Rosetta Therapeutics
Rosetta Therapeutics is a developer of new molecular matter as leads for the cure of neurodegenerative diseases.
Serenity Bioworks
Developing therapeutics derived from cellular stress pathways.
Sinfonia Biotherapeutics
Sinfonia Biotherapeutics Developing novel, bioreactor-delivered treatments for familial & genetically-defined neurodegenerative diseases.
SingletO2 Therapeutics
SingletO2 Therapeutics develops new treatments for periodontal disease using singlet oxygen.
TomegaVax
TomegaVax is developing cures for AIDS, malaria, tuberculosis, herpes, papillomavirus and hepatitis.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Zenobia Therapeutics
Zenobia Therapeutics is a focus on discovering treatments for neurodegenerative diseases using fragment-based lead discovery.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Edmund Sybertz Founder @ Lysosomal Therapeutics
Founder
Joseph Mazzulli Scientific Founder @ Lysosomal Therapeutics
Scientific Founder
Henri Termeer Founder @ Lysosomal Therapeutics
Founder
2014-01-01
Dimitri Krainc Scientific Founder, Chairman of the Scientific Advisory Board @ Lysosomal Therapeutics
Scientific Founder, Chairman of the Scientific Advisory Board
Mark Carthy Investor @ Lysosomal Therapeutics
Investor
2014-05-01
Founder
Investors List
Partners Innovation Fund
Partners Innovation Fund investment in Series A - Lysosomal Therapeutics
Orion Healthcare Equity Partners
Orion Healthcare Equity Partners investment in Series A - Lysosomal Therapeutics
Henri Termeer
Henri Termeer investment in Series A - Lysosomal Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series A - Lysosomal Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series A - Lysosomal Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Lysosomal Therapeutics
Lilly Ventures
Lilly Ventures investment in Series A - Lysosomal Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Lysosomal Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Seed Round - Lysosomal Therapeutics
Orion Healthcare Equity Partners
Orion Healthcare Equity Partners investment in Seed Round - Lysosomal Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-08-22 | Amylyx Pharmaceuticals | Lysosomal Therapeutics investment in Series A - Amylyx Pharmaceuticals | 5 M USD |
| 2015-09-22 | Artax Biopharma | Lysosomal Therapeutics investment in Series B - Artax Biopharma | 10 M USD |
| 2015-03-05 | Aura Biosciences | Lysosomal Therapeutics investment in Series B - Aura Biosciences | 21 M USD |
| 2011-11-07 | NanoString Technologies | Lysosomal Therapeutics investment in Series D - NanoString Technologies | 20 M USD |
Official Site Inspections
http://www.lysosomaltx.com
- Host name: server119-2.web-hosting.com
- IP address: 198.54.115.108
- Location: Los Angeles United States
- Latitude: 34.0318
- Longitude: -118.4252
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90064
More informations about "Lysosomal Therapeutics"
Lysosomal Therapeutics - Crunchbase Company Profile & Funding
Contact Email info@lysosomaltx.com Phone Number 617-913-0166 Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of …See details»
Lysosomal Therapeutics - VentureRadar
Our strategy leverages the clinically validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel …See details»
Lysosomal Therapeutics Company Profile | Management and
Www.lysosomaltx.com Lysosomal Therapeutics Profile and History Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of …See details»
Lysosomal Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Lysosomal Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Lysosomal Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Lysosomaltx.com. Private Company | Subsidiary Company | 2011 | Massachusetts, United States | < 10 | lysosomaltx.com. Last update 04 Mar 2025. Overview. Pipeline. Deal. ... The statistics …See details»
Lysosomal Therapeutics Inc. Overview | SignalHire Company Profile
By Q4 2019, Lysosomal Therapeutics Inc. has participated in at least 4 funding rounds and has raised a minimum of 38.0M. Funding decreased noticeable in Q4 2019 — by 5.0M compared …See details»
LYSOSOMAL THERAPEUTICS INC Cambridge MA, 02139
Free Business profile for LYSOSOMAL THERAPEUTICS INC at 19 Blackstone St, Cambridge, MA, 02139-3709, US. LYSOSOMAL THERAPEUTICS INC specializes in: Noncommercial …See details»
Lysosomal Therapeutics, Inc.:Company Profile & Technical …
Lysosomal Therapeutics, Inc. is a company that provides Pharmacy and Therapeutics, Neurodegeneration, Apomorphine and more. Lysosomal Therapeutics, Inc. is headquartered …See details»
Lysosomal Therapeutics - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Lysosomal Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Lysosomal Therapeutics Company Profile -Sales, Contacts, …
Lysosomal Therapeutics, Inc. (trade name LTI) is in the Medical Research business. View competitors, revenue, employees, website and phone number.See details»
Overview, News & Similar companies - ZoomInfo.com
Who is Lysosomal Therapeutics. Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding ne w …See details»
Lysosomal Therapeutics - Company Profile & Staff Directory
Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with …See details»
Lysosomal Therapeutics | VentureRadar
LTI's lead program targets Gaucher-related neurodegeneration, Parkinson's disease and other synucleinopathies. www.lysosomaltx.com VentureRadar Research / Company Website. …See details»
Lysosomal Therapeutics CEO and key executive team - Craft.co
Lysosomal Therapeutics's Founder, President and CEO, Director is Kees Been. Other executives include Carole Nuechterlein, Director; Andrew J. Sonderfan, VP of Toxicology & Early …See details»
Lysosomal Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Lysosomaltx.com. Private Company | 2011 | Massachusetts, United States | < 10 | lysosomaltx.com. Last update 23 Jan 2025. Overview. Pipeline. Deal. Translational Medicine. …See details»
Lysosomal Therapeutics Inc. Raises $20 Million in Series A Financing
Feb 3, 2015 www.lysosomaltx.com. Contacts. Company Contact Lysosomal Therapeutics Inc. Kees Been, 617-913-0166 CEO [email protected] or Media Contact MacDougall Biomedical …See details»
Lysosomal Therapeutics Inc. Receives $4.8 Million in Seed Funding
LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies. www.lysosomaltx.com. Contact: Lysosomal Therapeutics Inc. Kees Been, …See details»
Lysosomal Therapeutics Inc Overview - Salary.com
Discover essential details about Lysosomal Therapeutics Inc, including address, contact, and journey of our company's evolution.See details»
Lysosomal Therapeutics, Inc. (Lysosomal Therapeutics, Inc.) - 药物 …
May 1, 2023 了解Lysosomal Therapeutics, Inc. (Lysosomal Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的5项临床试验和6篇文献，疾病领域:神经系统疾病，内分泌 …See details»
Lysosomaltx's | UserLogos.org
Lysosomaltx's https://lysosomaltx.com transformative approach to severe neurological diseases marks a paradigm shift in the pharmaceutical landscape. By recognizing the interplay between …See details»